GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » 3-Year RORE %

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) 3-Year RORE % : -37.72% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Suzhou Zelgen Biopharmaceuticals Co's 3-Year RORE % for the quarter that ended in Sep. 2024 was -37.72%.

The industry rank for Suzhou Zelgen Biopharmaceuticals Co's 3-Year RORE % or its related term are showing as below:

SHSE:688266's 3-Year RORE % is ranked worse than
75.91% of 1370 companies
in the Biotechnology industry
Industry Median: -9.185 vs SHSE:688266: -37.72

Suzhou Zelgen Biopharmaceuticals Co 3-Year RORE % Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co 3-Year RORE % Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial - - -12.36 14.92 -16.19

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.25 -16.19 -22.34 -29.38 -37.72

Competitive Comparison of Suzhou Zelgen Biopharmaceuticals Co's 3-Year RORE %

For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Zelgen Biopharmaceuticals Co's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's 3-Year RORE % falls into.



Suzhou Zelgen Biopharmaceuticals Co 3-Year RORE % Calculation

Suzhou Zelgen Biopharmaceuticals Co's 3-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.66--2.18 )/( -4.03-0 )
=1.52/-4.03
=-37.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 3-year before.


Suzhou Zelgen Biopharmaceuticals Co  (SHSE:688266) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Suzhou Zelgen Biopharmaceuticals Co 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Suzhou Zelgen Biopharmaceuticals Co's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Zelgen Biopharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
Executives
Wu Li Qing Core technical personnel
Zhang Bin Core technical personnel
Huang Gang senior management
Lv Bin Hua Directors, senior managers, core technical personn
Lu Hui Ping Directors, senior managers
Gao Qing Ping senior management
Wu Ji Sheng Directors, senior managers, core technical personn
Zhang Jun Li senior management
Core technical personnel
Sheng Ze Lin Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co Headlines

No Headlines